Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme by Looker, H. C. et al.
                                                              
University of Dundee
Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening
Programme
Looker, H. C.; Nyangoma, S. O.; Cromie, D. T.; Olson, J. A.; Leese, G. P.; Black, M. W.;
Doig, J.; Lee, N.; Lindsay, R. S.; McKnight, J. A. ; Morris, Andrew; Pearson, D. W. M.; Philip,
S.; Wild, S. H.; Colhoun, H. M.; on behalf of the Scottish Diabetes Research Network
Epidemiology Group and the Scottish Diabetic Retinopathy Collaborative
Published in:
British Journal of Ophthalmology
DOI:
10.1136/bjophthalmol-2013-303948
Publication date:
2014
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Looker, H. C., Nyangoma, S. O., Cromie, D. T., Olson, J. A., Leese, G. P., Black, M. W., ... on behalf of the
Scottish Diabetes Research Network Epidemiology Group and the Scottish Diabetic Retinopathy Collaborative
(2014). Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme.
British Journal of Ophthalmology, 98(6), 790-795. 10.1136/bjophthalmol-2013-303948
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Rates of referable eye disease in the Scottish
National Diabetic Retinopathy Screening Programme
H C Looker,1 S O Nyangoma,1 D T Cromie,2 J A Olson,3 G P Leese,4 M W Black,5
J Doig,6 N Lee,5 R S Lindsay,7 J A McKnight,8,9 A D Morris,1 D W M Pearson,10
S Philip,11 S H Wild,9 H M Colhoun,1 on behalf of the Scottish Diabetes Research
Network Epidemiology Group and the Scottish Diabetic Retinopathy Collaborative
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
bjophthalmol-2013-303948).
For numbered affiliations see
end of article
Correspondence to
Helen C Looker, University of
Dundee, The MacKenzie
Building, Kirsty Semple Way,
Dundee DD2 4BF, UK;
h.c.looker@dundee.ac.uk
Received 1 July 2013
Revised 4 December 2013
Accepted 4 January 2014
Published Online First
5 March 2014
To cite: Looker HC,
Nyangoma SO, Cromie DT,
et al. Br J Ophthalmol
2014;98:790–795.
ABSTRACT
Aims Diabetic retinopathy screening aims to detect
people at risk of visual loss due to proliferative diabetic
retinopathy, but also refers cases of suspected macular
oedema (maculopathy). At the introduction of screening,
ophthalmology was concerned that referral rates would
be unmanageable. We report yield of referable disease
by referral reason for the first 5 years of the programme.
Methods We extracted screening results from a
nationwide clinical diabetes database to calculate annual
referral rates to ophthalmic clinics. We used logistic
regression to examine associations between clinical
measures and referable disease.
Results 182 397 people underwent ≥1successful
retinal screening between 2006 and 2010. The yield of
referable eye disease was highest in the first 2 years of
screening (7.0% and 6.0%) before stabilising at ∼4.3%.
The majority of referrals are due to maculopathy with
73% of referrals in 2010 based on a finding of
maculopathy.
Conclusions The commonest cause for referral is for
suspected macular oedema (maculopathy). Referral rates
for retinopathy have stabilised, as predicted, at relatively
low rates. However, ophthalmology workload continues
to rise as new treatment options (ie, monthly intraocular
injections) have unexpectedly increased the impact on
ophthalmology. A review of the screening referral path
for maculopathy may be timely.
INTRODUCTION
Diabetic retinopathy (DR) is one of the leading
causes of visual impairment in the UK,1 and treat-
ment to prevent vision loss requires early detection
and careful monitoring to be most effective.2
Following a Health and Technology Board
Assessment, Scotland launched a national Scottish
DR Screening service (DRS) in 2006. The principal
aim of screening was to prevent vision loss due to
proliferative DR (PDR), with individuals identified
as high risk being referred to eye clinics for assess-
ment and further management. Maculopathy
(MAC) did not meet the requirements to justify a
screening programme, but as it can be detected on
retinal photography, a MAC grading is included in
the DRS protocols with referral based on MAC as
well as DR grades. Based on pilot data from the
Grampian region the expected long-term referral
rate from the programme was expected to be 3–
4%. This workload was thought to be manageable
within existing ophthalmology provision.3 The aim
of this study is to report the yield of referable
disease over the first 5 years of the DRS (2006–
2010), a measure important for health service plan-
ning, and to estimate the burden due to referable
MAC.
METHODS
DRS protocols
The national roll out of the DRS began in 2006 to
improve availability of high quality retinal screening
in Scotland4 attaining nationwide coverage in 2007.
Patients eligible for screening are identified via the
national diabetes registry—the Scottish Care
Information-Diabetes Collaboration (SCI-DC) data-
base—which automatically captures data on people
with a diagnosis code for diabetes and has an esti-
mated current coverage of >99% of the Scottish
population with diagnosed diabetes mellitus (DM).
All new registrants on SCI-DC who are aged
≥12 years are automatically registered as new patients
on the DRS database and this triggers their first
appointment. Those who are already attending eye
clinics for DM-related eye disease, and those who are
too unfit or frail for screening, are suspended from
the screening programme with suspensions reviewed
at least every 3 years. The screening examination
involves a single central 45° field digital photograph
with mydriasis if required, and with centralised
grading.3 When photographic images are ungradable,
slit-lamp examination is undertaken within the
screening programme. Slit-lamp examination grad-
ings were not available for all health boards for
the whole time course of the study, but where
slit-lamp data are available it is included in the
results (within this study 4.2% of grades were from
slit-lamp exams). The use of a single central field for
detection of sight-threatening retinopathy has been
validated.5–8 The programme includes internal and
external quality control protocols to ensure the
quality of the photographs and the grading.9
DRS grading
The grading system in Scotland provides a DR
grade and a MAC grade (see online supplementary
table S1). Action is determined by the most severe
finding in the worst eye with grades of R3 (refer-
able background retinopathy), R4 (proliferative ret-
inopathy) or M2 (referable MAC) triggering
referral to a specialist eye clinic. Previous analyses
from the pilot phase of the DRS reported an
overall referral rate for eye disease of ∼3%.3 10
DRS grading data is automatically uploaded into
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the SCI-DC database. We use the results for the worst eye to
determine grading in this study.
Data sources
We used an anonymised extract of SCI-DC data that includes
data on all individuals alive and registered on SCI-DC as of 31
May 2008 (the most recent SCI-DC extract data available) which
has updated DRS data up to 31 December 2010. Data was
extracted from the SCI-DC audit server by an automated process
and then cleaned and anonymised prior to use in this study.
Study population
All individuals age >12 years who were registered on SCI-DC
with a diagnosis of diabetes before 31 May 2008 and had at least
one successful DRS examination were included in this study.
Covariate data
Diabetes type was based on the type listed in SCI-DC by clini-
cians. Additionally, we employed an algorithm to identify indivi-
duals at high risk of being mislabelled, based on age of diagnosis
and prescribed treatment. The date of diagnosis for DM was
based on the diagnosis date entered into SCI-DC by clinicians,
taking the earliest date where multiple dates were entered. This
diagnosis date was checked against multiple data sources includ-
ing prescription and hospital discharge records for any evidence
of diabetes prior to the SCI-DC date of diagnosis. Where there
is evidence of DM prior to the recorded date of diagnosis we
used the earliest date available.
To determine the risk factor profile for cases of referable eye
disease we considered risk factor data for those examined in
2008. Measures of Body Mass Index (BMI), HbA1c, serum total
cholesterol, systolic and diastolic blood pressure and smoking
status were selected from SCI-DC taking the measure made
nearest to the screening exam. In order to limit missing risk
factor data while retaining a temporal relationship between
measure and screening we used a series of cut-points (HbA1c
±180 days, blood pressure ±90 days and BMI or smoking status
±1085 days). If no measure was available the data was consid-
ered to be missing. We used prescription data to determine dia-
betes treatment at the time of the screening examination.
Statistical methods
The proportion of screened individuals with referable eye
disease was calculated by year. Where an individual had more
than one screening examination in a year the worst result was
used. We used univariate and multivariate logistic regression
models to examine the role of DM type, age, sex and diabetes
duration along with other covariates on risk for referable eye
disease. All statistical analysis was undertaken using SAS v.9.2
(Cary, North Carolina, USA). We used a p value of <0.05 to
indicate statistical significance.
RESULTS
There were 225 442 individuals eligible for inclusion in this
study. During the course of the study 187 822 (83.3%) were
screened at least once by the DRS, with 182 397 having at least
one gradable result (figure 1). Demographics for the study
population are shown in table 1.
Yield of referable eye disease
We included data on 560 362 screening episodes resulting in
gradable images between 2006 and 2010. Slit-lamp examina-
tions accounted for 23 311 (4.8%) of the data. Each individual
had a median of three (IQR 2–4) successful screens during the
study period and this did not differ by DM type (table 2). The
yield of referable eye disease was greatest in the first 2 years of
the programme where 7.0% and 6.0% of individuals success-
fully screened in the DRS had referable disease in 2006 and
2007, respectively. Over time, the proportion of people attend-
ing who had attended at least one previous screen by the DRS
Figure 1 Flow diagram to demonstrate use of DRS among individuals
from SCI-DC during the period 1 January 2006–31 December 2010.
DRS, Diabetic Retinopathy Screening service; SCI-DC, Scottish Care
Information-Diabetes Collaboration.
Table 1 Baseline demographics for population
Frequency/median
Male sex 100 733 (55.2%)
Diabetes type (%)
Type 1 diabetes 20 521 (11.3)
Type 2 diabetes 161 135 (88.3)
Other/unknown type 741 (0.4)
Year first screened (%)
2006 39 463 (21.6)
2007 89 720 (49.2)
2008 33 777 (18.5)
2009 11 142 (6.1)
2010 8295 (4.6)
Age at first screen (years) 64 (54–73)
Diabetes duration at first screen (years) 5.7 (2.4–10.8)
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increased from 23.5% of screens in 2007 to >90% of screens
in 2009 and 2010. Referral rates were highest for first-time
attendees with 6.9% of first screens finding referable eye disease
compared to 3% for people attending their 4th or 5th screen.
For 2008 and onwards, the yield was stable at 4.3%. For all
years, the yield for referable MAC was higher than that for
referable DR accounting for between 60% of referrals in 2006
to 73% in 2010. Overall, the referral rates were higher for
those screened by slit-lamp (7.2%) than those screened by
retinal photography (5.1%).
Referable eye disease by type of diabetes
We excluded 741 individuals from this analysis as they had
neither type 1 (T1DM) nor type 2 (T2DM) (eg, MODY, pancre-
atic causes, etc; table 3). There were 20 521 people with T1DM
and 161 135 people with T2DM (table 2). The prevalence of
referable eye disease was consistently higher among those with
T1DM compared to those with T2DM (table 3). The propor-
tion of referrals due to MAC alone were similar for both types
of DM in 2006 (59.0% for T1DM and 60.3% for T2DM), but
in subsequent years the proportion rose among the T2DM
population to 76.1% in 2010 compared to 63.2% of the refer-
rals among the T1DM population.
Risk factor profile for referable eye disease
Table 4 shows the risk factor profile by retinal screening grade.
Regardless of diabetes type, compared to the no retinopathy
group, those with referable disease were more often male, with
longer DM duration, higher HbA1c, and higher systolic blood
pressure. Additionally, for people with T1DM, referable disease
was also associated with older age, higher BMI, higher diastolic
blood pressure and higher prevalence of smoking. By contrast,
in T2DM, referable disease was also associated with lower
prevalence of smoking, lower BMI and greater use of insulin
therapy.
Compared to people referred for DR, people referred with
MAC had shorter DM duration and lower HbA1c values.
Additionally, among people with T1DM, MAC referrals tended
to be for older women with higher BMI than referrals for DR,
whereas for people with T2DM, MAC referral was associated
with lower BMI and lower systolic blood pressure,
In multivariate models restricted to those with no missing
data (n=78 814) including all covariates and screening mode
male sex, longer DM duration and higher HbA1c remained sig-
nificantly associated with referable disease regardless of DM
type. For T2DM, higher blood pressure, lower prevalence of
smoking and higher prevalence of insulin use were also asso-
ciated with referable disease.
In a univariate logistic regression model for the presence of
any referable eye disease using data for 2008, the OR for
T1DM compared to T2DM was 3.08 (95% CI 2.89 to 3.28,
p<0.001), with risk seemingly mediated principally via DM
duration (OR for referral due to T1DM 0.81 (95% CI 0.73 to
0.91) after adjustment for age, sex, DM duration and screening
method). T1DM was a positive risk factor for referral due to
PDR even after adjustment for age, sex and DM duration and
screening method (OR=1.35, OR 1.06 to 1.73, p=0.017).
However, due to the limited overlap between age and DM dur-
ation ranges for the DM types (table 4) these models may not
fully account for the covariates.
DISCUSSION
The yield of referable eye disease within the DRS was at its
highest during the first 2 years of the programme (2006–2007)
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when 7% of successfully screened individuals were referred to
the eye clinic. Since 2008, the annual referral rate has been
stable at 4.3% (∼5500 referrals per year). This suggests that the
DRS successfully screened people who had been missed by
earlier non-national screening programmes and has now reached
a steady level. This workload should be manageable within
existing ophthalmology provision.3 In keeping with this, we
showed that referable disease was more commonly found at an
individual’s initial screening which reflects our earlier work on
screening intervals.11 However, despite the screening pro-
gramme being designed for the prevention of sight loss due to
PDR, 73% of referrals in 2010 were for suspected macular
oedema. That so many of the referrals are due to suspected
macular oedema is important as we are facing a shift in treat-
ment options for macula oedema. While patients with diabetic
macular oedema used to be routinely offered a finite course of
laser treatment, patients are now being offered monthly, indefin-
ite, intraocular injections. As laser for macular oedema cannot
restore vision, it was important to offer treatment to patients,
even when asymptomatic. However, new treatments restore
vision in many, albeit at the cost of indefinite monthly intraocu-
lar injections.12 13 This new development questions the need to
detect patients with macular oedema while they are still asymp-
tomatic, suggesting the way the DRS deals with macula oedema
deserves review. Of note, this study is based on the finding of
referable disease and, thus, is not influenced by clinical factors
that may influence whether an individual attends eye clinic sub-
sequent to screening.
Strengths of the study are the inclusion of data from a national
DR screening programme. The DRS methodology has also been
validated for detection of sight-threatening DR,5–8 and while there
have been adjustments to the grading algorithm over time these
changes have not effected the referable disease gradings which
have remained consistent. As Scotland also has a means for linking
an individual’s medical data from a variety of sources (via a unique
health identifier the CHI number) we can incorporate clinical data
to the DR screening data. There are also weaknesses to the study.
Primarily, the current data extract only includes individuals diag-
nosed with DM prior to 31 May 2008. Therefore, for the years
2008–2010, we are missing data on people with DM diagnosed
after 31 May 2008. We do not believe this will have greatly altered
the prevalence of referable eye disease reported in the study, as
referable disease is very rare in newly diagnosed people with
T1DM,14 and in this population <2% of individuals with newly
diagnosed T2DM have referable retinopathy at their first screening
examination.15 Thus, it is probable that our estimate of yield is
higher than the true. We also cannot report outcomes of referral as
we lack data from eye clinics.
The reported overall referral rates are in line with those pro-
posed during the pilot stage of the DRS 3 and in keeping with
reports of regional data from England.16 The principle risk
factors we identified as associated with referable eye disease at
screening are in keeping with those reported for DR as a whole,
and are independent of the screening method (slit-lamp vs pho-
tography), that is, hyperglycaemia, hypertension, DM dur-
ation17 and insulin therapy for T2DM.18 The role of BMI as a
risk factor for retinopathy is less clear-cut with positive associa-
tions reported in T1DM19 and T2DM,20 21 while the associ-
ation we report between lower BMI and referable MAC in
T2DM is consistent with findings from the WESDR.18 Similarly,
there is inconsistent data for the role of smoking and referable
eye disease.22 23
In the USA, the prevalence of sight-threatening retinopathy
among people with T1DM is as high as 30%.24 In the past, for
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people with DM of >20 years duration, the prevalence of any
DR among people with T1DM approaches 100% 14 compared
to ∼60% in people with T2DM.18 24 However, recent data
from Wisconsin shows a lower prevalence of DR at 20 years
DM duration for people diagnosed with T1DM in 1987–1992
compared with those diagnosed prior to 1980.25
While we may see reductions in the prevalence of referable
disease over time due to improvements in DM management, the
current referral rates indicate a steady rate of new referrals from
the national screening programme with the majority a result of
referable MAC rather than of referable DR. A review of the
referral pathway for MAC to better reflect the changing treat-
ment options could have a significant impact on the screening
pathway and on ophthalmology workload.
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Table 4 Risk factors for referable eye disease for individuals with type 1 or type 2 diabetes in 2008
No retinopathy
or maculopathy
Non-referable
retinopathy
Referable
maculopathy
only
Referable
retinopathy
±referable
Maculopathy
p Value
No retinopathy
vs Referable
maculopathy
p Value
No retinopathy
vs referable
retinopathy
p Value
Referable
maculopathy vs
referable
retinopathy
Type 1 diabetes 5872 6146 856 521
Male sex* 3122 (53.2%) 3415 (55.6%) 498 (58.2%) 331 (63.5%) 0.006 <0.001 0.049
Age (years) 35.1±16.9 42.6±14.5 43.8±13.8 41.8±12.3 <0.001 <0.001 0.046
Diabetes duration (years)† 7.7 (3.6–14.4) 19.6 (12.3–28.9) 20.7 (15.4–28.2) 23.1 (17.0–30.0) <0.001 <0.001 <0.001
HbA1c (%) 8.5±1.7 8.7±1.6 9.1±1.7 9.4±1.9 <0.001 <0.001 0.002
Systolic blood pressure
(mm Hg)
126.5± 16.4 130.2±17.1 132.5±15.8 132.9±18.1 <0.001 <0.001 0.409
Diastolic blood pressure
(mm Hg)
73.8±10.0 74.3±9.9 76.3±10.2 76.0±10.8 <0.001 <0.001 0.351
BMI (kg/m2) 25.9±5.4 27.2±5.0 27.8±5.1 26.8±5.3 <0.001 0.003 0.009
Current smoking* 851 (15.1%) 1200 (20.7%) 159 (20.0%) 114 (23.8%) 0.048 0.003 0.130
Type 2 diabetes 80 961 29 951 2941 1187
Male sex* 44 615 (55.1%) 17 535 (58.6%) 1672 (56.9%) 708 (59.7%) 0.062 0.002 0.100
Age (years) 64.8±11.5 65.3±11.4 64.8±11.5 65.1±11.5 0.710 0.220 0.293
Diabetes duration (years)† 4.8 (2.4–8.1) 7.8 (4.1–12.8) 11.3 (6.2–16.2) 13.2 (7.4–18.1) <0.001 <0.001 <0.001
HbA1c (%) 7.3±1.4 7.6±1.6 8.1±1.8 8.4± 1.8 <0.001 <0.001 <0.001
Systolic blood pressure
(mm Hg)
134.3±15.9 136.3±17.1 138.4±18.0 139.9±20.6 <0.001 <0.001 0.043
Diastolic blood pressure
(mm Hg)
75.7±10.2 75.3±10.2 75.8±10.4 75.7±10.4 0.886 0.818 0.837
BMI (kg/m2) 31.6±6.3 31.4±6.3 31.2±6.3 31.9±6.5 0.001 0.037 <0.001
Current smoking* 10 306 (14.5%) 3797 (14.6%) 310 (12.1%) 129 (12.1%) <0.001 0.015 0.874
Diabetes treatment* <0.001 <0.001 <0.001
No medication 25 464 (31.5%) 5729 (19.1%) 321 (10.9%) 111 (9.4%)
Oral agents only 49 332 (60.9%) 18 593 (62.1%) 1652 (56.2%) 579 (48.8%)
Insulin 6165 (7.6%) 5629 (18.8%) 968 (32.9%) 497 (41.9%)
Data are means with SDs except for * which are frequencies, and † which are medians with IQR.
Referable eye disease comprises referable maculopathy (M2 on the DRS grading scheme), preproliferative retinopathy (R3 on the DRS grading scheme) and proliferative retinopathy (R4
on the DRS grading scheme).
p Values are for multivariate logistic regression models including all covariates and screening modality (retinal photography or slit-lamp).
Covariate data was complete for 78 814 (61.4%) of the individuals. Blood pressure data was missing for 31 767 (24.7%) Smoking data was missing for 15 101 (11.8%) HbA1c data
was missing for 9946 people (7.7%) and BMI data was missing for 7025 people (5.5%).
BMI, Body Mass Index; DRS, Diabetic Retinopathy Screening service.
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